Thursday, 4 June 2026
EMA-AMA Ebola response collaboration, AI integration in Australian healthcare, Senate hearing on bulk billing
- 01
EMA and AMA Collaborate on Ebola Outbreak Response
The European Medicines Agency (EMA) is collaborating with the African Medicines Agency (AMA) and national regulatory authorities to address the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda, caused by the Bundibugyo virus. This marks the first public health emergency collaboration between EMA and AMA since the latter's establishment. The partnership aims to develop clinical trial designs and medical countermeasures, as there are currently no authorised vaccines or treatments for Bundibugyo virus disease. Promising candidates for clinical trials include various vaccine and treatment options, with discussions already underway to advance these medical countermeasures.
- 02
Australia's Slow Progress on Medical Data and AI Criticised
Dr John Halamka, president of the Mayo Clinic Platform, will address the Wild Health summit in Canberra next month, highlighting the urgent need for Australia to advance its integration of AI and health data. A recent Productivity Commission report warns that inaction on healthcare reform could lead to significant costs and worsening outcomes. Despite the potential benefits of a National Prevention and Early Intervention Framework, progress remains stalled. The summit aims to explore the implications of demographic changes on the healthcare system and the role of AI in addressing these challenges.
- 03
Senate Hearing Sparks Debate on Bulk Billing Practices
During a recent Senate estimates hearing, opposition health spokeswoman Anne Ruston accused Labor MPs of pressuring GPs into adopting bulk billing practices. Finance Minister Katy Gallagher defended the MPs, stating that urging GPs to bulk bill is appropriate engagement. Ruston highlighted concerns that 30% of GP practices could be financially disadvantaged by switching to universal bulk billing. Additionally, Labor Senator Dr Michelle Ananda-Rajah raised issues of potential backlash against GPs in regional areas who choose to bulk bill, likening it to cartel behaviour. The discussion reflects ongoing tensions surrounding bulk billing policies in Australia.
- 04
NSW contraceptive prescribing trial favours affluent women
The evaluation of the NSW pharmacist-led contraceptive prescribing trial reveals that it primarily benefited wealthy women in metropolitan areas, rather than those with limited access to care. The University of Newcastle report assessed around 2000 women who accessed oral contraceptive resupply from pharmacies over a 12-month period, showing a high patient satisfaction score of 91.6 out of 100. Despite the trial's aim to improve accessibility, 80% of participants were from metropolitan areas with a high concentration of GPs, raising concerns about equity in healthcare access. AMA NSW GP chair Dr Ken McCroary expressed worries that the trial may neglect women in less advantaged areas who require comprehensive care.
- 05
$18 million review of Support at Home assessment algorithm announced
The federal government will allocate $18.1 million to review the integrated assessment tool (IAT) used for determining Support at Home funding levels. This decision follows ongoing criticism from clinicians and sector groups regarding the algorithm's inability to allow human override of its outcomes. Concerns have been raised about the IAT's effectiveness in identifying key risks for older Australians, including frailty and sensory impairment. The review aims to address these issues and assess the algorithm's operational effectiveness in the context of aged care reforms.
- 06
Education Key to Long-Term Eczema Management in Children
Eczema affects approximately one third of Australian children under six, yet many struggle to manage the condition effectively. Education for children and their carers is essential for achieving long-term control, focusing on ongoing skin care rather than reactive treatment. Current guidelines recommend daily use of emollients and topical corticosteroids to manage symptoms. Barriers to effective management include limited understanding of eczema, concerns about treatments, and practical issues related to adherence. A case study highlights the need for consistent moisturiser application to improve outcomes.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.